Physician profile
Leslie E Mccrary-Etuk
NPI 1174670418
$611.36
in general payments reported to CMS, 2019-2025
11 companies · $134 in 2025
The $134 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66.70 · 2020: $79.41 · 2021: $81.67 · 2022: $51.96 · 2023: $106 · 2024: $91.22 · 2025: $134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $332.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $331.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $221.33 | 2020-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $114.77 | 2019-2020 | |
| Lilly USA, LLC | $77.23 | 2021-2025 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $72.84 | 2023-2025 | Cologuard Collection Kit |
| Hologic Sales and Service, LLC | $24.76 | 2025 | Aptima, Third Wave, Thinprep 2000 Processor |
| Nevro Corp. | $22.84 | 2022 | |
| Cranial Technologies, INC | $17.61 | 2025 | Doc Band |
| Mimedx Group, INC. | $15.86 | 2024 | |
| Janssen Biotech, INC. | $15.77 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $15.48 | 2024 | Farxiga |
| Abbvie INC. | $12.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Mccrary-Etuk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.